Stada Group
Bryan Kim has a diverse background in various industries, with experience in executive roles at companies like STADA Group, Samsung Bioepis, Boehringer Ingelheim, Pfizer, and Intel Corporation. Bryan holds an MBA from Yale School of Management and a BA in Public Health/Pre-med from The Johns Hopkins University. Bryan's expertise spans across business development, marketing, sales, and regional management.
This person is not in any offices
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.